Skip to main content
Erschienen in: Critical Care 1/2020

Open Access 15.07.2020 | COVID-19 | Research Letter

Prone positioning under VV-ECMO in SARS-CoV-2-induced acute respiratory distress syndrome

verfasst von: Bruno Garcia, Nicolas Cousin, Claire Bourel, Mercé Jourdain, Julien Poissy, Thibault Duburcq, on behalf of the Lille Intensive Care COVID-19 group

Erschienen in: Critical Care | Ausgabe 1/2020

Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ARDS
Acute respiratory distress syndrome
ICU
Intensive care unit
PP
Prone positioning
VV-ECMO
Veno-venous extracorporeal membrane oxygenation
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
FiO2
Fraction of inspired oxygen
PaO2
Arterial partial pressure of oxygen
FDO2
Fraction on oxygen delivered in the sweep gas
ECL
Extensive lung consolidation

Background

Infection due to severe acute respiratory coronavirus 2 (SARS-CoV-2) may lead to an atypical acute respiratory distress syndrome (ARDS) [1], requiring in the most severe cases veno-venous extracorporeal membrane oxygenation (VV-ECMO). The management of persistent severe hypoxemia under VV-ECMO requires a multi-step clinical approach including prone positioning (PP), which could improve oxygenation [2].

Methods

We performed a retrospective study of patients with SARS-CoV-2-induced ARDS submitted to PP during VV-ECMO. We aimed to describe mechanical ventilation parameters and gas exchanges before and after PP. We assess the safety of PP and compare patients with PP under ECMO (prone ECMO group) to those maintained in the supine position (supine ECMO group). Patients were treated in accordance with the recommendation guidelines on ARDS [3]. During VV-ECMO, PP was considered in case of severe hypoxemia (PaO2/FiO2 ratio below 80 mmHg) despite FDO2 and FiO2 both at 100% and in case of extensive lung consolidation (ECL) on chest imaging (> 50% of lung volume).

Results

We enrolled 208 COVID-19 patients. Among the 125 patients with ARDS, 25 (20%) required VV-ECMO, and 14 (56%) were placed at least once in PP for a total of 24 procedures with a median duration of 16 (15–17) h. The delay from ECMO implantation therapy to PP was 1.5 days [13]. The resultant changes in ventilator/ECMO settings and blood gas analysis before and after PP are displayed in Table 1. The median PaO2/FiO2 ratio improvement after PP was 28% [2–36]. High responders (increase PaO2/FiO2 ratio > 20%) were 62.5%, moderate-responders (increase PaO2/FiO2 < 20%) were 16.7%, and non-responders (decrease PaO2/FiO2) were 20.8%. We did not observe any major safety concerns but only pressure sores after 6 procedures, three minor hemorrhages at the injection cannula, and three moderate drops in VV-ECMO flow requiring fluid resuscitation. Pre-ECMO characteristics, ventilator/ECMO settings, and outcomes are exposed in Table 2. Patients in the prone ECMO group were less likely to be weaned from ECMO, and 28-day mortality rate was significantly higher.
Table 1
The resultant changes in ventilator/ECMO settings and blood gas analysis before and after PP
Variables
Before prone position
After prone position
P value
Mechanical ventilation settings
 Tidal volume (mL/kg)
2.4 (1.8–2.9)
2.4 (1.8–2.7)
0.42
 RR (breaths/min)
20 (16–25)
19 (16–25)
0.87
 Plateau airway pressure (cmH2O)
28 (26–32)
29 (28–32)
0.43
 PEEP (cmH2O)
14 (12–18)
16 (12–20)
0.36
 Respiratory system compliance (mL/cmH2O)
18.6 (13.7–25.9)
17.9 (12.8–26.5)
0.92
 Driving pressure (cmH2O)
14.5 (12–16.5)
14.5 (11–16)
0.56
 Inspired fraction of oxygen (%)
70 (60–100)
67.5 (52.5–95)
0.16
ECMO settings
 ECMO blood flow (L/min)
6.2 (6–6.7)
6 (5.8–6.7)
0.41
 Sweep gas flow (L/min)
7 (6–8.5)
7 (6.8–9)
0.15
 FDO2 (%)
100 (80–100)
100 (80–100)
0.56
Gas analysis
 PaO2 (mmHg)
64 (51–78)
82 (66–109)
0.007
 PaO2/FiO2 (mmHg)
84 (73–108)
112 (83–157)
0.002
 PaCO2 (mmHg)
44 (41–46)
42 (36–49)
0.27
 pH
7.38 (7.35–7.43)
7.38 (7.34–7.42)
0.47
Data are expressed as number (%) or median [IQR]. Analyses were performed with the GraphPad Prism 6 software (San Diego, CA). All tests were two-tailed, with α level at 0.05. The comparisons before vs. after prone position were realized by Wilcoxon matched-pairs signed-rank test
RR respiratory rate, PEEP positive end-expiratory pressure, FiO2 fraction of inspired oxygen, PaCO2 arterial partial pressure of carbon dioxide, PaO2 arterial partial pressure of oxygen, FDO2 fraction on oxygen delivered in the sweep gas, ECMO extracorporeal membrane oxygenation
Table 2
Pre-ECMO characteristics, ventilator/ECMO settings, and outcomes
 
All patients (n = 25)
Prone ECMO (n = 14)
Supine ECMO (n = 11)
P value
Age (years)
59 (49.5–63)
59 (48–63)
57 (48–66)
0.82
Male sex, n (%)
22 (88)
12 (85.7)
10 (90.9)
1
Body mass index (kg/m2)
32 (28.4–37.5)
31.5 (28–38)
33.6 (28.4–37.6)
0.86
Comorbidities
 Any, n (%)
6 (24)
3 (21.4)
3 (27.3)
1
 Hypertension, n (%)
12 (48)
6 (42.8)
6 (54.5)
0.7
 Diabetes, n (%)
10 (40)
5 (35.7)
5 (45.4)
0.7
SAPS II
60 (40–65)
59.5 (46–62)
61 (38–80)
0.39
Delay symptoms-ECMO (days)
16 (11–18)
15 (11–20)
16 (10–16)
0.94
Delay mechanical ventilation-ECMO (days)
7 (4–10)
6.5 (4–10)
7 (4–13)
0.99
Chest imaging (X-rays or CT)
 Consolidation, n (%)
14 (56%)
11 (78.6)
3 (27.3)
0.02
 Ground glass opacity, n (%)
25 (100)
14 (100)
11 (100)
 Bilateral infiltration, n (%)
25 (100)
14 (100)
11 (100)
PaO2/FiO2 ratio before ECMO (mmHg)
84 (69–98)
84 (67–96)
87 (66–102)
0.77
Prone position before ECMO, n (%)
25 (100)
14 (100)
11 (100)
Neuromuscular blockers, n (%)
25 (100)
14 (100)
11 (100)
iNO before ECMO, n (%)
21 (84)
12 (85.7)
9 (81.8)
1
Corticosteroids, n (%)
4 (16)
1 (7.1)
3 (27.3)
0.29
MV and ECMO settings the first day of ECMO
 Tidal volume (mL/kg)
2.6 (1.9–2.9)
2.4 (1.7–3.1)
2.6 (2.1–2.8)
0.71
 Plateau airway pressure (cmH2O)
26 (23–29)
26 (25–29)
26 (21–29)
0.52
 PEEP (cmH2O)
14 (11–20)
14 (12–20)
14 (10–20)
0.47
 Driving pressure (cmH2O)
10 (9–13)
11 (10–14)
9 (8–12)
0.44
 Respiratory rate (cycles/min)
14 (12–18)
18 (13–25)
12 (12–14)
0.006
 Respiratory system compliance (mL/cmH2O)
25 (15–32)
24 (14–30)
28 (18–33)
0.36
 Inspired fraction of oxygen (%)
50 (50–80)
55 (50–72.5)
50 (40–80)
0.53
 ECMO blood flow (L/min)
5.9 (5–6.3)
5.8 (5.2–6.7)
5.9 (4.9–6)
0.31
 Sweep gas flow (L/min)
5 (4–6)
5.5 (4.5–6.2)
4 (3.5–5)
0.04
 Membrane lung fraction of oxygen (%)
100 (80–100)
100 (80–100)
100 (90–100)
0.38
Outcomes
 ECMO weaning, n (%)
11 (44)
3 (21.4)
8 (72.7)
0.02
 ECMO duration (days)
10 (5–13)
11 (6–13)
6 (3–12)
0.28
 28-day mortality, n (%)
14 (56)
11 (78.6)
3 (27.3)
0.02
 Discharged alive from ICU, n (%)
10 (40)
2 (14.3)
8 (72.7)
0.005
 Still in ICU, n (%)
1 (4)
1 (7.1)
0
1
Data are expressed as number (%) or median [IQR]. Analyses were performed with the GraphPad Prism 6 software (San Diego, CA). All tests were two-tailed, with α level at 0.05. To compare the prone ECMO group to the supine ECMO group, we used the non-parametric Mann-Whitney test for continuous variables and the exact Fisher test for categorical ones
SAPS II Simplified Acute Physiology Score, IQR interquartile range, CT computed tomography, PaO2 arterial partial pressure of oxygen, FiO2 fraction of inspired oxygen, PEEP positive end-expiratory pressure, ECMO extracorporeal membrane oxygenation, ICU intensive care unit

Discussion

We report that during VV-ECMO, PP improved oxygenation without a change in respiratory system compliance and PaCO2 at constant levels of minute ventilation and sweep gas flow. This does not suggest lung recruitment by PP but rather an optimization of ventilation and perfusion matching. Three explanations could be advanced for the mortality rate in the prone ECMO group (78.6%). First, prone ECMO patients may be more severe than supine ECMO patients. As described by Gattinoni et al., worsening patients progress from type 1 to type 2 (higher percentage of non-aerated tissue) [1], which is associated with a higher mortality rate [4]. Prone ECMO patients had much more consolidations, obviously because ECL was the main indication to be prone (n = 10/14). Furthermore, prone ECMO patients need a higher respiratory rate for a higher sweep gas flow suggesting that they may be exposed to a higher mechanical power, and they possibly had also a higher dead space. Second, postmortem biopsies, performed in 6 patients with ECL in the prone ECMO group, found a fibrin exudative presence both in the alveolar spaces and bronchioles followed by a fibroblastic phase [5] and raise the question of the use of corticosteroids (only one patient in the prone ECMO group). Third, as already described by Zeng et al. [6], more than half (8/11) of the patients died from septic shock and multiple organ failure, for which ECMO may be useless.

Conclusion

Prone positioning under VV-ECMO improves oxygenation in SARS-CoV-2-induced ARDS without compromising the safety of the patients. The high mortality rate in prone ECMO patients may be explained by the greater illness severity and the lack of an immunomodulatory therapy such as corticosteroids.

Acknowledgements

The authors are indebted to thank the whole members of the Lille Intensive Care COVID-19 Group and the entire nursing staff of the intensive care unit of the “Roger Salengro Hospital” of the “Centre Hospitalier Universitaire de Lille.”.
Lille Intensive Care COVID-19 group:
Pauline Boddaert1 (Pauline.​boddaert@chru-lille.​fr), Arthur Durand1 (Arthur.​durand@chru-lille.​fr), Ahmed El Kalioubie1 (Ahmed.​elkalioubie@chru-lille.​fr), Patrick Girardie1 (Patrick.​girardie@chru-lille.​fr), Marion Houard1 (Marion.​houard@chru-lille.​fr), Geoffrey Ledoux1 (Geoffrey.​ledoux@chru-lille.​fr), Anne Sophie Moreau1 (Annesophie.​moreau@chru-lille.​fr), Christopher Niles1 (Christopher.​niles@chru-lille.​fr), Saad Nseir1 (Saad.​nseir@chru-lille.​fr), Thierry Onimus1 (Thierry.​onimus@chru-lille.​fr), Aurelia Toussaint1 (Aurelia.​toussaint@chru-lille.​fr), Sebastien Préau1 (Sebastien.​preau@chru-lille.​fr), Laurent Robriquet1 (Laurent.​robriquet@chru-lille.​fr), Anahita Rouze1 (Anahita.​rouze@chru-lille.​fr), Arthur Simonnet1 (Arthur.​simonnet@chru-lille.​fr), Sophie Six1 (Sophie.​six@chru-lille.​fr), Morgan Caplan1 (morgan.​caplan@chru-lille.​fr), Julien Goutay1 (julien.​goutay@chru-lille.​fr), Emmanuelle Jaillette1 (emmanuelle.​jaillette@chru-lille.​fr), Erika Parmentier-Decrucq1 (erika.​decrucq@chru-lille.​fr), Raphael Favory1 (raphael.​favory@chru-lille.​fr), Daniel Mathieu1 (daniel.​mathieu@chru-lille.​fr), Guillaume Degouy (Guillaume.​degouy@chru-lille.​fr), Mouhamed Moussa2 (Mouhamed.MOUSSA@CHRU-LILLE.FR)
1Pôle de Réanimation, CHU Lille, University of Lille, F-59000 Lille, France
2Service d’Anesthésie-Réanimation Cardio-Vasculaire, CHU Lille, University of Lille, F-59000 Lille, France
French institutional authority for personal data protection (National Commission for Information Technology and Freedom, registration no DEC20-086) and ethics committee (ID-CRB 2020-A00763-36) approved the study.
Not applicable

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020;24(1):154.CrossRef Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020;24(1):154.CrossRef
2.
Zurück zum Zitat Kimmoun A, Roche S, Bridey C, Vanhuyse F, Fay R, Girerd N, Mandry D, Levy B. Prolonged prone positioning under VV-ECMO is safe and improves oxygenation and respiratory compliance. Ann Intensive Care. 2015;5(1):35.CrossRef Kimmoun A, Roche S, Bridey C, Vanhuyse F, Fay R, Girerd N, Mandry D, Levy B. Prolonged prone positioning under VV-ECMO is safe and improves oxygenation and respiratory compliance. Ann Intensive Care. 2015;5(1):35.CrossRef
3.
Zurück zum Zitat Papazian L, Aubron C, Brochard L, Chiche J-D, Combes A, Dreyfuss D, Forel JM, Guérin C, Jaber S, Mekontso-Dessap A, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9:69.CrossRef Papazian L, Aubron C, Brochard L, Chiche J-D, Combes A, Dreyfuss D, Forel JM, Guérin C, Jaber S, Mekontso-Dessap A, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9:69.CrossRef
4.
Zurück zum Zitat Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PloS One. 2020;15(3):e0230548.CrossRef Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PloS One. 2020;15(3):e0230548.CrossRef
5.
Zurück zum Zitat Copin M-C, Parmentier E, Duburcq T, Poissy J, Mathieu D, Lille COVID-19 ICU and Anatomopathology Group. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med. 2020.46(6):1124-1126. Copin M-C, Parmentier E, Duburcq T, Poissy J, Mathieu D, Lille COVID-19 ICU and Anatomopathology Group. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med. 2020.46(6):1124-1126.
6.
Zurück zum Zitat Zeng Y, Cai Z, Xianyu Y, Yang BX, Song T, Yan Q. Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series. Crit Care. 2020;24(1):148.CrossRef Zeng Y, Cai Z, Xianyu Y, Yang BX, Song T, Yan Q. Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series. Crit Care. 2020;24(1):148.CrossRef
Metadaten
Titel
Prone positioning under VV-ECMO in SARS-CoV-2-induced acute respiratory distress syndrome
verfasst von
Bruno Garcia
Nicolas Cousin
Claire Bourel
Mercé Jourdain
Julien Poissy
Thibault Duburcq
on behalf of the Lille Intensive Care COVID-19 group
Publikationsdatum
15.07.2020
Verlag
BioMed Central
Schlagwort
COVID-19
Erschienen in
Critical Care / Ausgabe 1/2020
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-020-03162-4

Weitere Artikel der Ausgabe 1/2020

Critical Care 1/2020 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.